TITLE

Stroke prevention in nonvalvular atrial fibrillation

AUTHOR(S)
Albers, Gregory W.; Atwood, J. Edwin; Hirsch, Jack; Sherman, David G.; Hughes, Robert A.; Connolly, Stuart J.; Albers, G W; Atwood, J E; Hirsh, J; Sherman, D G; Hughes, R A; Connolly, S J
PUB. DATE
November 1991
SOURCE
Annals of Internal Medicine;11/1/91, Vol. 115 Issue 9, p727
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
There has been considerable uncertainty about the best way to prevent stroke in patients with nonvalvular atrial fibrillation. Recent studies have suggested that low-dose warfarin therapy, in addition to producing fewer bleeding complications, may be as effective as higher-dose therapy in preventing thromboembolic events. Four large, prospective, randomized trials have examined the risks and benefits of warfarin therapy for stroke prophylaxis in patients with nonvalvular atrial fibrillation. All four studies showed a substantially reduced incidence of stroke and a low incidence of significant bleeding in patients treated with warfarin. One of these studies also showed that aspirin reduced the incidence of stroke. The benefits associated with long-term low-dose warfarin therapy appear to exceed the risks for serious bleeding in most patients with atrial fibrillation. Aspirin may be a viable therapeutic option for patients who are unable to take warfarin or for those in subgroups at a low risk for stroke.
ACCESSION #
6976529

 

Related Articles

  • Predictors of Warfarin Use in Atrial Fibrillation Patients in the Inpatient Setting. Agarwal, Shuchita; Bennett, Dimitri; Smith, David J. // American Journal of Cardiovascular Drugs;2010, Vol. 10 Issue 1, p37 

    Background: There is substantial published evidence that warfarin reduces the risk of stroke in patients with atrial fibrillation (AF). However, the current literature suggests that not all patients who could benefit from warfarin receive the drug. Objective: To evaluate patient-related...

  • Another Warfarin Replacement on Horizon. Elliott, William T. // Neurology Alert;Jan2011 Phamacology Watch, p1 

    The article discusses the Stroke Prevention Using the Oral Direct Factor Xa Inhibitor Rivaroxaban Compared With Warfarin in Patients with Nonvalvular Atrial Fibrillation (ROCKET AF) study which revealed the efficacy of rivaroxaban as another warfarin replacement for preventing stroke and blood...

  • Performing Cardioversion: Dabigatran Therapy vs. Warfarin. DiMarco, John P. // Clinical Cardiology Alert;Mar2011, Vol. 30 Issue 3, p19 

    In this article the author discusses the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial, which reported that both dabigatran and warfarin are effective in patients with atrial fibrillation (AF) undergoing cardioversion. He comments on the implications of the study's...

  • Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation? Eckman, Mark H.; Greenberg, Steven M.; Rosand, Jonathan // JGIM: Journal of General Internal Medicine;May2009, Vol. 24 Issue 5, p543 

    Background: Genetic variants of the warfarin sensitivity gene CYP2C9 have been associated with increased bleeding risk during warfarin initiation. Studies also suggest that such patients remain at risk throughout treatment.Objective: Would testing patients with...

  • NEW TECHNIQUE THWARTS STROKES FROM A-FIB.  // RN;Sep2009, Vol. 72 Issue 9, p14 

    This article discusses a study about a possible new technique as an alternative to warfarin treatment, percutaneous closure of the left atrial appendage, for use in atrial fibrillation patients who are at a high risk for stroke. The researchers selected patients with non-valvular atrial...

  • Clopidogrel-aspirin an option in AF.  // Pulse;4/8/2009, Vol. 69 Issue 12, p3 

    The article reports on the findings of a randomised controlled trial in patients with atrial fibrillation, conducted by researchers in London, England. The study found that combined therapy with clopidogrel and aspirin may reduce the risk of stroke. It also revealed that the combination of...

  • Dabigatran may be a cost-effective alternative to warfarin for stroke prevention in atrial fibrillation.  // Formulary;Feb2011, Vol. 46 Issue 2, p39 

    The article reports on research on prescription drugs that was published in the "Annals of Medicine." Researchers evaluated the oral direct thrombin inhibitor dabigatran and found that it may be cost-effective compared to a therapy of adjusted-dose warfarin in patients requiring anticoagulation...

  • Dabigatran vs Warfarin for AFib.  // Neurology Alert;Dec2010 Primary Care, p24 

    The article discusses research by L. Wallentin and colleagues, published in a 2010 issue of "Lancet," on the effectiveness and safety of dabigatran compared with warfarin in stroke prevention in atrial fibrillation.

  • Direct Thrombin Inhibitor for Atrial Fibrillation. DiMarco, John P. // Clinical Cardiology Alert;Nov2009, Vol. 28 Issue 11, p85 

    The article discusses research on the efficacy of dabigatran (DAB) and warfarin (WRF) against bleeding in patients with atrial fibrillation (AF). It references the study "Dabigatran Versus Warfarin in Patients With Atrial Fibrillation," by S. J. Connolly et al, published in a 2009 issue of the...

  • MANAGEMENT OF NONVALVULAR ATRIAL FIBRILLATION: A COMPREHENSIVE APPROACH. Iuliano, Luigi; Di Matteo, Antonio; Straface, Giuseppe // Indian Journal of Medical Sciences;Sep2009, Vol. 63 Issue 9, p419 

    Atrial fibrillation is the most common arrhythmia in clinical practice, may coexist with conditions common to both cardiovascular and noncardiovascular diseases and is associated with considerable morbidity and mortality. Atrial fibrillation is often asymptomatic and diagnosed only when it has...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics